HIV Treatment Breakthrough: Age is Just a Number!
Aging doesn't have to mean diminished HIV control. A recent study reveals that the long-acting injectable duo of cabotegravir and rilpivirine (CAB + RPV) is a powerful ally for seniors in the fight against HIV. But here's where it gets intriguing: despite facing more health challenges, older adults in the study showed remarkable resilience and treatment adherence.
Methodology and Findings:
In a comprehensive analysis of the RELATIVITY cohort, researchers examined the real-world impact of CAB + RPV across 58 Spanish healthcare institutions. They focused on 3146 individuals with HIV who had achieved virologic suppression before switching to the long-acting injectable.
The study compared 370 participants aged 60 and above (median age 63, mostly male) with 2775 younger participants (median age 43, also predominantly male). The primary goal was to assess virologic suppression and failure rates, defined by specific HIV-1 RNA values.
Results? At 15 months, HIV suppression rates remained impressively high and similar between the age groups (97.3% in seniors vs. 96.8% in younger adults). Virologic failure was rare and comparable (0.3% vs. 0.7%).
But wait, there's more: older participants were more likely to permanently discontinue treatment (7.8% vs. 6.1%), yet this difference wasn't statistically significant. Interestingly, seniors had lower baseline CD4+ and CD8+ counts but maintained stable immunologic parameters.
And this is the part most people miss: Treatment adherence was significantly higher in the older group (89.3% vs. 83.7%), but they experienced more systemic adverse events (1.6% vs. 0.8%).
Real-World Implications:
The RELATIVITY study offers a ray of hope, suggesting that CAB + RPV is a viable and well-tolerated option for older HIV patients, even with multiple health issues and a history of complex medication regimens.
Study Details and Limitations:
Led by Jesús Troya from Hospital Universitario Infanta Leonor in Madrid, the study was published online in HIV Medicine on October 21, 2025. While the ambispective design posed some recall and information bias risks, standardized electronic records helped minimize these issues. The short follow-up period, however, limited long-term outcome assessments.
Disclosure and Editorial Notes:
The study received no external funding. Notably, two authors disclosed lecture fees from pharmaceutical companies, unrelated to this research. This article was crafted with AI assistance and meticulously reviewed by human editors.
Related Reads:
- Lenacapavir and bNAbs: A Powerful HIV-1 Suppression Duo [https://www.eatg.org/hiv-news/lenacapavir-and-bnabs-maintain-hiv-1-suppression/]
- Early HIV Drugs: A Temporary Immune System Reprieve [https://www.eatg.org/hiv-news/early-hiv-drugs-give-immune-system-a-brief-reprieve-before-dysregulation-returns-study-finds/]
- Low-Dose THC: Reducing HIV Treatment Side Effects [https://www.eatg.org/hiv-news/low-dose-thc-reduces-side-effects-of-hiv-treatment/]
Get Involved and Stay Informed:
Are you personally impacted by HIV/AIDS or dedicated to supporting those affected? Join our community, and let's make a difference together! Become a member or support our cause.
Stay updated with the latest HIV news and co-infection insights. Subscribe to our newsletters and ensure you never miss a beat in the fight against HIV and co-infections.
